LONDON & BURLINGAME, Calif.--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication ...

New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm The FDA-approved strength for both COPD and asthma is fluticasone furoate / ...

Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to contact a healthcare provider immediately if symptoms occur. Use Trelegy Ellipta with ...

(Reuters) - GlaxoSmithKline Plc said on Wednesday the U.S health regulator approved its lung disease drug Trelegy Ellipta for expanded use, making it the first inhaler delivering three drugs at once ...

The FDA approves the use of GlaxoSmithKline's (GSK +0.5%) Trelegy Ellipta [fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI)] for the long-term, once-daily ...

GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion today supporting the use ...

GlaxoSmithKline has seized the initiative with its three-drug COPD inhaler Trelegy Ellipta despite some new competition from AstraZeneca. To cement its lead, GSK is looking for a first-of-its-kind ...

Gordon Stewart-Harrison recalls his first experience with chronic obstructive pulmonary disease (COPD) when he was shoveling snow on his driveway. After just a few moments, he was completely out of ...